The prognostic impact of white-coat hypertension is not yet completely clear. In this study, we investigated cardiovascular outcome in sustained hypertension, white-coat hypertension and normotension in the short and long term. The occurrence of fatal and nonfatal cardiovascular events was evaluated in 1732 subjects with clinical hypertension (1333 with sustained and 399 with white-coat hypertension) and 305 with normotension. White-coat hypertension was defined as clinical hypertension and daytime blood pressure o135/85 mm Hg. During the period of observation (mean 6.4 years, range 0.7-13.1), 152 cardiovascular events occurred. The event rate per 100 patient-years in subjects with normotension, white-coat and sustained hypertension was 0.38, 0.44 and 1.58, respectively. Event-free survival was significantly different among the groups (Po0.0001). After adjustment for several covariates, Cox regression analysis showed that cardiovascular risk was significantly higher in patients with sustained than in those with white-coat hypertension (relative risk (RR) 3.32, 95% confidence interval (CI) 1.81-6.12, P ¼ 0.0001), whereas there was no significant difference between normotension and white-coat hypertension. When events were analysed separately, cardiac and cerebrovascular risk were significantly higher in sustained than in whitecoat hypertension (RR 4.16, 95% CI 1.48-11.6, P ¼ 0.007, and RR 4.12, 95% CI 1.62-10.5, P ¼ 0.003, respectively) and not significantly different between white-coat hypertension and normotension. Event-free survival had the same trend for the whole period of observation both when cardiovascular events were examined together and when cardiac and cerebrovascular events were analysed separately. In this study, cardiovascular risk in white-coat hypertension was significantly lower than that in sustained hypertension and not significantly different from normotension both in the short and long term.
Introduction
White-coat hypertension 1, 2 (WCH), a condition characterized by high clinical but normal ambulatory blood pressure (BP), has been widely studied in the past few years.
At present, however, it still remains a matter of controversy because its prognostic relevance is incompletely understood. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Some studies have evaluated the prognostic impact of WCH in the short term. [3] [4] [5] [6] [7] The aforesaid studies reported that cardiovascular risk was significantly lower in subjects with WCH than in those with sustained hypertension (SH), [3] [4] [5] [6] [7] and similar between WCH and normotension. 3, 5, 7 It has been questioned whether the lower risk in WCH could persist over longer observational periods.
In this context, other studies [8] [9] [10] [11] [12] [13] [14] [15] have been performed, reporting conflicting results. Some of these studies [8] [9] [10] [11] reported a lower risk in WCH when compared to SH, whereas others [12] [13] [14] [15] reported a similar risk. When compared to normotension, some studies [9] [10] [11] reported a similar risk in WCH, whereas others [12] [13] [14] [15] reported a higher risk. These studies [8] [9] [10] [11] [12] [13] [14] [15] were heterogeneous regarding the method used to define WCH, the cutoff values employed, the endpoints included and the populations studied. Thus, other studies are needed to add further insight into the clinical relevance of WCH during longer observational periods.
In the present study, we evaluated cardiovascular outcome in subjects with SH, WCH and normotension in the short and long term.
Methods

Subjects
We studied 1732 clinically hypertensive patients, 1333 with SH and 399 with WCH, and 305 normotensive subjects. Patients with antihypertensive treatment at baseline (present or previous), secondary hypertension, previous cardiovascular events, diabetes mellitus and renal disease were excluded from this study. Hypertensive subjects were selected from the hypertensive population referred to our centre. Normotensive subjects were members of the hospital staff, subjects examined for reasons other than hypertension or cardiovascular disease and without any relevant systemic disease, and other volunteers referred to our centre by their family doctors. All the patients underwent clinical evaluation, electrocardiography, routine laboratory tests, echocardiographic examination and non-invasive ambulatory BP monitoring. Study population came from the same geographical area (Chieti and Pescara, Abruzzo, Italy). The study was in accordance with the Second Declaration of Helsinki and was approved by the institutional committee on human research. Subjects gave informed consent.
Office BP measurements
Clinical systolic and diastolic BP recordings were performed by a physician with the subject in the supine position after 10 min of rest, using a mercury sphygmomanometer and appropriate-sized cuffs. Phase V was used to determine diastolic BP. Measurements were performed in triplicate and the average value was used as the BP for the visit. Clinical hypertension was defined as systolic BP X140 mm Hg and/or diastolic BP X90 mm Hg at each of three visits. Clinical normotension was defined as BPo140/90 mm Hg.
Ambulatory BP monitoring
Ambulatory BP monitoring was performed with a portable non-invasive recorder (SpaceLabs 90207) on a day of typical activity. Technical aspects have been reported previously. 16 Ambulatory BP readings were obtained at 15-min intervals from 0600 hours to 2400 hours, and at 30-min intervals from 2400 hours to 0600 hours. The following ambulatory BP parameters were evaluated: average daytime (awake period), nighttime (asleep period) and 24-h systolic and diastolic BPs. Awake and asleep periods were calculated from diary times. Recordings were automatically edited. 16 Follow-up Subjects were followed up in our hospital outpatient clinic or by their family doctors. Patients' characteristics and the occurrence of cardiovascular events were recorded during follow-up visits or by telephone interview of the patient followed by a clinical visit. Hospital record forms were collegially reviewed by the authors of this study. Cardiovascular events included fatal and nonfatal myocardial infarction (at least two of three standard criteria: typical chest pain, electrocardiographic changes and transient elevation of conventional myocardial enzymes by more than twofold the upper normal limits), coronary revascularization (bypass surgery or angioplasty), heart failure requiring hospitalization (at least two major or one major plus two minor Framingham criteria), 21 fatal and nonfatal stroke (rapid onset of localizing neurological deficit lasting X24 h with computer tomography evidence) and peripheral revascularization (bypass surgery or angioplasty).
Statistical analysis
Data are expressed as mean ± s.d. or percentage. Groups were compared with one-way analysis of variance followed by a multiple comparison test, and w 2 or Fisher's exact test, where appropriate. Event rates are expressed as the number of events per 100 patient-years based on the ratio of the observed number of events to the total number of patient-years of exposure up to the terminating event or censor. Survival curves were estimated using the Kaplan-Meier product-limit method and compared by the Mantel (log-rank) test. 22 The effect of various covariates on survival was evaluated by using the backward stepwise Cox regression model (significance levels for inclusion and exclusion were 0.05 and 0.1, respectively). 22 Covariates included in the Cox model were age (years), gender (men vs women), family history of premature cardiovascular disease, that is, men at age o55 years and women at age o65 years (yes vs no), smoking habit (yes vs no), body mass index (kg m -2 ), clinical systolic BP (mm Hg), low-density lipoprotein (LDL) cholesterol (mg per 100 ml), creatinine (mg per 100 ml), LV hypertrophy (yes vs no), ambulatory BP group (WCH vs normotension, SH vs normotension and SH vs WCH), aspirin use (yes vs no), statin use (yes vs no) and antihypertensive drug class at the last follow-up. Adjusted relative risks and 95% confidence intervals were calculated for the significant Cox model factors. Statistical significance was defined as Po0.05 (twotailed). Analyses were made with the SPSS 12 software package (SPSS Inc., Chicago, IL, USA).
Results
The main characteristics and BP of study groups at baseline are reported in Table 1 . Prevalence of men, family history of premature cardiovascular disease and LV hypertrophy was higher in patients with SH than in those with WCH and normotension. Total and LDL cholesterol were higher in the SH group than in the other two groups. Fasting serum glucose was higher in patients with SH than in those with WCH. Clinical BP was higher in patients with SH and WCH than in those with normotension, and in patients with SH than in those with WCH. Ambulatory BP (day, night and 24-h) was significantly higher in the SH group than in the other two groups by definition. Day, night and 24-h systolic BPs were slightly but significantly higher in subjects with WCH than in those with normotension. The other variables reported in Table 1 were not significantly different among the groups.
Drug therapy of study groups is reported in Table 2 . At the last follow-up 7.2, 46.6 and 94.2% of subjects in the group with normotension, WCH and SH, respectively, were taking antihypertensive medications. Almost all drug classes were more frequently used in patients with SH and WCH than in those with normotension and in patients with SH than in those with WCH. Aspirin and statin use was not significantly different among the groups.
During the period of observation from December 1992 to December 2005 (mean 6.4 years, range 0.7-13.1), 152 cardiovascular events occurred. Specifically, there were 46 myocardial infarctions (3 fatal), 16 coronary revascularizations, 9 heart failure requiring hospitalization, 73 strokes (7 fatal) and 8 peripheral revascularizations. There were 7 (3 myocardial infarctions and 4 strokes), 12 (3 myocardial infarctions, 1 coronary revascularization, 5 strokes and 3 peripheral revascularizations) and 133 (40 myocardial infarctions, 15 coronary revascularizations, 9 heart failures, 64 strokes and 5 peripheral revascularizations) events in the normotensive, WCH and SH group, respectively.
The event rates per 100 patient-years and eventfree survival curves in subjects with normotension, WCH and SH are reported in Figures 1 and 2 , respectively.
To identify independent predictors of outcome, a Cox regression analysis was performed. Age, smoking habit, LDL cholesterol, LV hypertrophy and SH resulted independent predictors of cardiovascular events, whereas there was no significant difference between WCH and normotension. Main results are reported in Table 3 . When clinical systolic BP was forced into the model, the results did not change.
When cardiac and cerebrovascular events were analysed separately, event-free survival curves showed the same trend of total cardiovascular events ( Figures 3 and 4) .
Cox regression analysis indicated that cardiac and cerebrovascular risk were significantly higher in SH than in WCH (relative risk (RR) 4.16, 95% confidence interval (CI) 1.48-11.6, P ¼ 0.007, and RR 4.12, 95% CI 1.62-10.5, P ¼ 0.003, respectively) and not significantly different between WCH and normotension. Po0.05 vs white-coat hypertension.
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Discussion
In the present study, we have found that subjects with WCH had a significantly better prognosis than those with SH both in the short and long term. Our finding concerns total, cardiac and cerebrovascular events. These results extend our previous report, 7 including subjects with uncomplicated mild clinical hypertension with a shorter follow-up. Some studies assessed the prognostic impact of WCH in the short term, [3] [4] [5] [6] [7] reporting a better prognosis in WCH than in SH, [3] [4] [5] [6] [7] and similar prognosis in WCH and normotension. 3, 5, 7 Other studies evaluated the prognostic impact of WCH over longer periods. [8] [9] [10] [11] [12] [13] [14] [15] Khattar et al. 8 studied 459 hypertensive patients followed for a mean period of 9.1 years. WCH was found to be associated with a lower cardiovascular risk (present vs absent hazard ratio (HR) 0.29, 95% CI 0.09-0.90, P ¼ 0.04). 8 A normotensive control group could not be included in that study. 8 Fagard et al. 9 studied 391 older patients (X60 years) during a median follow-up of 10.9 years. They observed that in patients with WCH, prognosis was better than in those with SH and similar to those with normotension. 9 Ohkubo et al.
10 studied 1332 subjects aged X40 years from a general population of a Japanese community. During a mean follow-up of 10.2 years, cardiovascular risk was similar between subjects with WCH and those with normotension (RR 0.95, 95% CI 0.39-2.33), and significantly higher in those with SH.
Hansen et al. 11 studied 1700 Danish subjects from a general population. Through a mean follow-up of 9.5 years, cardiovascular risk was not significantly different between WCH and normotension (RR 0.66, 95% CI 0.30-1.44) and significantly higher in SH.
Our results are in line with the aforementioned studies. [8] [9] [10] [11] However, one study 8 could not include a normotensive group, one 9 was performed in older patients and two 10, 11 evaluated a general population. The present data, obtained in a hypertensive population including middle-aged and older subjects and in a normotensive group, extend previous findings.
Strandberg et al. 12 studied 536 businessmen followed for 21 years. Groups were defined according to the difference between physician's and nurse's BPs (WCH was defined as physician's BP 4160 or 95 mm Hg and nurse's BPo140 or 90 mm Hg). Cardiovascular death was higher in subjects with WCH than in those with normotension (RR 4.1, 95% CI 1.03-16.1). It should be noted that unconventional method and reference limits were used to define WCH, 22 probably leading to a misclassification of subjects. 23 Moreover, a population at increased risk for its characteristics, not representative of the hypertensive one, has been studied. Finally, cardiovascular morbidity was not evaluated. 12 Thus, for the reasons reported above, it is difficult to compare our study with that by Strandberg et al. 12 Gustavsen et al.
13 studied 344 patients with SH, 76 with WCH and 146 with normotension followed for a mean duration of 10.2 years. WCH was defined as clinical hypertension and daytime BPo135/ 90 mm Hg. 13 After adjustment for some covariates, cardiovascular risk was higher in WCH than in normotension (RR 6.6, Po0.001).
13 It should be noted that a cutoff higher than usual has been employed. When a lower cutoff value was used, about 50% of WCH subjects were reclassified as SH subjects and the results were less impressive. Moreover, a composite end point, including, in addition to other major events, angina, transient ischaemic attack, dissecting aortic aneurysm, renal artery stenosis and carotid artery stenosis, has been reported. These end points were not included in our study and in others. Finally, in multivariate analysis, some important covariates could not be included. 13 Thus, the differences between our study and that by Gustavsen et al.
13 make the comparison difficult.
Verdecchia et al. 14 studied 4406 subjects with hypertension and 1549 normotensive controls from four prospective studies who were followed for a median duration of 5.4 years. WCH was defined as clinical hypertension and daytime BPo130/ 80 mm Hg. The stroke rate was 0.35, 0.59 and 0.65 in the group with normotension, WCH and SH, respectively. Results were comparable using a threshold of 135/85 mm Hg to define WCH. In multivariate analysis, the adjusted HR for stroke was 1.15, 95% CI 0.61-2.16, P ¼ 0.66, in the WCH group compared with the normotensive one. In the short term, stroke risk was higher in SH than in WCH and similar between WCH and normotension. After the sixth year of follow-up, the incidence of stroke tended to increase in subjects with WCH, and the corresponding hazard curve crossed that of subject with SH by the ninth year of study. It was concluded that, although WCH was not associated with an increased risk of stroke during the global Figure 3 Cardiac event-free survival curves in subjects with normotension, white-coat hypertension and sustained hypertension. Figure 4 Stroke-free survival curves in subjects with normotension, white-coat hypertension and sustained hypertension.
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14 This study has the strength of a high number of events. However, the natural history of subjects with WCH is not yet clear. It has been reported that part of them could develop SH during time. 24, 25 Thus, it could be interesting to know whether events occurred in subjects with persistent WCH or in those who developed SH. Moreover, unlike the abovementioned study, 14 diabetic subjects were not included in our report.
Mancia et al. 15 studied 1001 subjects with normotension, 356 with WCH, 172 with masked hypertension and 495 with SH followed for 12 years. WCH was defined as clinical hypertension and 24-h BPo125/79 mm Hg. When adjusted for age and gender, the risk for cardiovascular death tended to be higher in subjects with WCH than in those with normotension, but did not attain statistical significance. 15 After further adjustment for serum cholesterol, blood glucose and smoking, only a trend for increased risk of cardiovascular death in WCH was observed again. In contrast to our study, Mancia et al. 15 evaluated a general population, reported data on mortality but not morbidity, used a different cutoff value to define WCH and could not include some covariates in the multivariate analysis.
Recently, Fagard and Cornelissen 26 published a meta-analysis on the incidence of cardiovascular events in true normotension, WCH, masked hypertension and SH obtained from the same study population. The overall adjusted HR vs normotension was 1.12, 95% CI 0.84-1.50, P ¼ 0.59, for WCH and 2.28, 95% CI 1.87-2.87, Po0.001, for SH. Our results, although in the present report normotensive subjects were not obtained from the same study population, are in line with the abovementioned meta-analysis.
The present study has some limitations. First, there were few events in the normotensive and WCH groups, probably because of their intrinsic low risk profile. Second, our normotensive group was healthy and it cannot be excluded that the risk of a general normotensive population could have been underestimated to some extent. Third, we studied only Caucasian subjects and our results cannot be applied to other ethnic groups. Fourth, as patients' management was mainly based on clinical BP, part of the subjects with WCH received drug therapy; it is unclear whether the same results would have been achieved if all of them had remained untreated. Further studies are needed to address this issue. However, it has been reported 4,27 that in WCH, drug therapy reduces clinical but not ambulatory BP, which is more closely associated with prognosis, and that cardiovascular outcome is not significantly different between subjects with WCH treated with placebo or active treatment. 4 Last, the mean followup duration of this report was lower than in some others. [8] [9] [10] [11] [12] [13] 15 In conclusion, in this study, subjects with WCH had a better prognosis than those with SH both in the short and long term.
While it seems 3-7 that WCH carries a low risk in the short term, considering this report and other studies, [8] [9] [10] [11] [12] [13] [14] [15] it appears that its prognostic impact in the long term remains uncertain. Further studies are needed to clarify this aspect definitively. It is needed, particularly, to establish the risk of future events in untreated and treated subjects with WCH and to evaluate whether a possible risk increase in the long term is associated with the development of SH.
